Abstract
We retrospectively analyzed the antifungal usage in children with acute myeloid leukemia (AML). Overall, 211 of 304 patients (69.4%) received a total of 389 antifungal treatment episodes. In 234 episodes, initial antifungal treatment consisted of amphotericin B [as monotherapy, n = 193; median dosage (range) of amphotericin B deoxycholate 0.6 mg/kg per day (0.02–1.5 mg/kg per day) and of liposomal amphotericin B 3.0 mg/kg per day (0.6–30 mg/kg per day)], in 149 episodes of fluconazole [as monotherapy, n = 143; 5 mg/kg per day (1–29 mg/kg per day)], in 40 of flucytosine [as monotherapy, n = 1; 150 mg/kg per day (40–370 mg/kg per day)], and in 9 of itraconazole [as monotherapy, n = 8; 6 mg/kg per day (1.6–20 mg/kg per day)]. We conclude that the majority of children with AML receives at least one episode of antifungal therapy. Inappropriate dosing and combination of antimycotics need to be addressed in future educational measures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Riley LC, Hann IM, Wheatley K, Stevens RF (1999) Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 106:436–444
Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T (2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384–4393
Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U (2004) Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 18:72–77
Cesaro S, Strugo L, Alaggio R, Cecchetto G, Rigobello L, Pillon M, Cusinato R, Zanesco L (2003) Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer 11:722–727
Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB (2005) Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 27:135–140
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14
Kern W, Behre G, Rudolf T, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wormann B, Buchner T, Hiddemann W (1998) Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 83:291–301
Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis 39 Suppl 1:S11–S14
Martin MT, Gavalda J, Lopez P, Gomis X, Ramirez JL, Rodriguez D, Len O, Jordano Q, Ruiz I, Rosal M, Almirante B, Pahissa A (2003) Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 52:1032–1034
Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, Bearden DT (2007) Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf. DOI 10.1002/pds.1365
Perfect J, Klotman M, Gilbert C, Crawford D, Rosner G, Wright K et al (1992) Prophylactic intravenous amphotericin B in neutropenic autologous marrow transplant recipients. J Infect Dis 165:891–897
Baddley JW, Pappas PG (2005) Antifungal combination therapy: clinical potential. Drugs 65:1461–1480
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751
Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ (2006) Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711–e716
Zaoutis TE, Prasad P-A, Heydon KH, Walsh TJ (2006) The utilization of antifungals in 26 United States children’s hospitals. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract no M-905
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehrnbecher, T., Kaiser, J., Varwig, D. et al. Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93. Eur J Clin Microbiol Infect Dis 26, 735–738 (2007). https://doi.org/10.1007/s10096-007-0362-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-007-0362-9